Positive preclinical results for Can-Fite's CF102

Israeli firm Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, says that its CF102 drug, which is being developed for the treatment of viral hepatitis and liver cancer, was tested in preclinical trials and shown to be effective in promoting liver tissue regeneration following partial hepatectomy. The company filed a patent application on this innovative findings and will include this indication in further clinical development of CF102.

Partial hepatectomy is usually performed in patients with primary or metastatic liver cancer. Rapid liver regeneration is crucial in these conditions and determines future liver function and chances for successful recovery. Regeneration of normal liver tissue is also needed to preserve liver function in patients with liver failure. No drugs are currently available to speed up the regeneration process; therefore, developing a drug for the treatment of patients undergoing hepatectomy or patients with liver failure is at need.

Similar to CF101, Can-Fite's first drug which is currently in Phase IIb clinical studies, CF102 specifically attacks liver tumors and hepatitis-infected cells. The novel indication for regeneration of normal liver tissue extends the use of CF102 to include treatment of patients undergoing partial hepatectomy and patients suffering from diseases leading to liver failure.